Abstract
Data from the NICHE-2 study indicate that patients with operable mismatch repair-deficient colon cancer benefit considerably from neoadjuvant immune checkpoint inhibition. A brief period of treatment with nivolumab and ipilimumab induced high pathologic response rates, did not delay surgery, and checked disease recurrence for a median of 13.1 months so far.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
